MUSC Hollings Cancer Center | Strategic Alliance Partners

MUSC Hollings Cancer Center is South Carolina’s only National Cancer Institute-designated cancer center, with the largest academic-based cancer research program in the state. The cancer center comprises more than 120 faculty cancer scientists and 20 academic departments. It has an annual research funding portfolio of more than $44 million and is dedicated to preventing and reducing the cancer burden across South Carolina. Hollings offers state-of-the-art diagnostic capabilities, therapies and surgical techniques within multidisciplinary clinics that include surgeons, medical oncologists, radiation therapists, radiologists, pathologists, psychologists and other specialists equipped for the full range of cancer care, including more than 200 clinical trials across South Carolina. For more information, visit hollingscancercenter.musc.edu

Latest from MUSC Hollings Cancer Center


MUSC Hollings Cancer Center Appoints Pancreatic Cancer Surgeon Scientist William Hawkins, MD, As Deputy Director

January 04, 2024

William Hawkins, MD, will join MUSC Hollings Cancer Center on January 1, 2024, as deputy director, where he will focus on strengthening translational research, increasing clinical trials across South Carolina and assisting Craig Lockhart, MD, with making clinical operations more efficient.

New Approvals Help Fill Unmet Need in Treating Chronic GVHD

July 26, 2022

A panel of hematology experts discuss use of steroids in the first-line setting as well as several subsequent-line treatments that have recently received FDA approval for patients with steroid-refractory chronic GVHD, which affects up to 50% of patients.

New Study Expands Lifesaving Smoking Cessation Efforts to Rural, Underserved Communities

December 23, 2021

MUSC Hollings Cancer Center researchers hope to save lives by expanding the Tobacco Treatment Program, first implemented at MUSC Health in 2014, to rural and underserved communities to improve overall patient health, save patients money and reduce the number of premature deaths.

Research Project Aims to Make CAR-T-cell Therapy Safer and More Effective

October 11, 2021

A new project led by researchers at MUSC Hollings Cancer Center could significantly decrease the side effects associated with CAR-T-cell therapy and make the treatment available to more patients who could benefit.

Dr. Carolyn Britten on Next Steps in Immunotherapy

September 15, 2015

Carolyn D. Britten, MD, chief, Division of Hematology Oncology, associate director, Clinical Investigations, at the Hollings Cancer Center, Medical University of South Carolina, discusses questions that remain in immunotherapy.

Hollings Cancer Center Researcher Receives Prestigious Governor's Award for Science

March 30, 2015

Dr. Matthew J. Carpenter, an associate professor at the Medical University of South Carolina and researcher with the MUSC Hollings Cancer Center, is the recipient of the 2015 Governor's Young Scientist Award for Excellence in Scientific Research.